CO2023000118A2 - Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos) - Google Patents

Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos)

Info

Publication number
CO2023000118A2
CO2023000118A2 CONC2023/0000118A CO2023000118A CO2023000118A2 CO 2023000118 A2 CO2023000118 A2 CO 2023000118A2 CO 2023000118 A CO2023000118 A CO 2023000118A CO 2023000118 A2 CO2023000118 A2 CO 2023000118A2
Authority
CO
Colombia
Prior art keywords
compositions
treatment
osa
methods
sleep apnea
Prior art date
Application number
CONC2023/0000118A
Other languages
English (en)
Spanish (es)
Inventor
Sudhanshu Agarwal
Mark Robert Bleackley
Joel Bradley Latham
Original Assignee
Incannex Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902368A external-priority patent/AU2020902368A0/en
Application filed by Incannex Healthcare Ltd filed Critical Incannex Healthcare Ltd
Publication of CO2023000118A2 publication Critical patent/CO2023000118A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0000118A 2020-07-09 2023-01-06 Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos) CO2023000118A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020902368A AU2020902368A0 (en) 2020-07-09 A method of treatment
PCT/AU2021/050734 WO2022006636A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (osa)

Publications (1)

Publication Number Publication Date
CO2023000118A2 true CO2023000118A2 (es) 2023-04-17

Family

ID=79553355

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000118A CO2023000118A2 (es) 2020-07-09 2023-01-06 Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos)

Country Status (8)

Country Link
US (1) US20230310364A1 (enExample)
EP (1) EP4178568A4 (enExample)
JP (1) JP7796718B2 (enExample)
AU (1) AU2021306424A1 (enExample)
CA (1) CA3182528A1 (enExample)
CO (1) CO2023000118A2 (enExample)
IL (1) IL299212A (enExample)
WO (1) WO2022006636A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023289652A1 (en) * 2022-06-21 2024-12-12 Apnimed, Inc. (Delaware) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor
AU2023404665A1 (en) * 2022-11-29 2025-07-17 Incannex Healthcare Limited A method of treating obstructive sleep apnoea (osa)
WO2025107039A1 (en) * 2023-11-23 2025-05-30 Incannex Healthcare Limited Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
EP3746068A4 (en) * 2018-01-29 2021-11-03 Evero COMPOSITIONS AND METHODS OF TREATMENT FOR OBSTRUCTIVE SLEEP APNEA
WO2019180706A1 (en) * 2018-03-19 2019-09-26 Bol Pharma Ltd. Methods and compositions for treating epilepsy and associated disorders
CN117177741A (zh) * 2021-04-16 2023-12-05 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合

Also Published As

Publication number Publication date
AU2021306424A1 (en) 2023-01-19
CA3182528A1 (en) 2022-01-13
JP7796718B2 (ja) 2026-01-09
JP2023533289A (ja) 2023-08-02
US20230310364A1 (en) 2023-10-05
IL299212A (en) 2023-02-01
EP4178568A4 (en) 2024-10-16
WO2022006636A1 (en) 2022-01-13
EP4178568A1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
PY2040196A (es) Uso de cannabidiol en el tratamiento del síndrome de dravet
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
ES2518116T3 (es) Terapia contra el cáncer con un parvovirus combinado con un inhibidor de HDAC
CL2012001844A1 (es) Metodo para el tratamiento del sindrome de apnea obstructiva del sueño que comprende la administración de un inhibidor de la anhidrasa carbónica y un agente adicional seleccionado de modafinilo, agente sedante no benzodiazepina, y combinaciones de los mismos; una formulacion farmacéutica; una preparacion farmaceutica empaquetada.
MX2022013081A (es) Compuestos para el tratamiento de sars.
PE20120998A1 (es) Metodos para el tratamiento del cancer usando antagonistas de notch
ECSP12011865A (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
PH12021552745A1 (en) Methods for the administration of certain vmat2 inhibitors
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
MX2020008086A (es) Metodos y composiciones para tratar la apnea del sue?o.
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2008000613A1 (es) Uso del acido (s,s)-(1-aminometil-3,4-dimetil-ciclopentil)-acetico para preparar un medicamento util para tratar tinnitis en un mamifero.
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
CL2021002676A1 (es) Nutrición en los primeros años
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
ECSP22077573A (es) Método para el tratamiento de afecciones asociadas a covid-19
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
CO2023012342A2 (es) Inhibidores de enzimas
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.